Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the study details, indicating the content is blocked from access. This reflects a change in accessibility rather than the study data itself.SummaryDifference21%

- Check36 days agoChange DetectedThe page shows a new revision number in the footer, updating from v3.6.5 to v3.6.6, which indicates a backend or frontend update without content changes.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page revision label was updated from v3.6.4 to v3.6.5, indicating a minor maintenance update to the page version. No study content or data were changed.SummaryDifference0.0%

- Check65 days agoChange DetectedA new publication citation has been added to the Publications section. It references a Nat Commun 2026 article on Copanlisib and Nivolumab in MSS colorectal cancer, expanding the study's bibliographic references.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page revision was updated to v3.6.4, replacing the previous v3.6.3. This reflects an update to the page's revision metadata rather than changes to study data.SummaryDifference0.0%

- Check93 days agoChange DetectedThe revision tag on the page was updated from v3.6.2 to v3.6.3, signaling a newer version of the page template or backend update. This change does not modify study content, eligibility criteria, or results.SummaryDifference0.0%

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.